|
Market Closed -
Nasdaq
16:00:00 2026-08-19 EDT
|
5-day change | 1st Jan Change | ||
| 840.84 USD | +3.78% |
|
+5.50% | +8.94% |
| 08-19 | Regeneron Pharmaceuticals Wins US FDA Approval For Pasatru In Ultra-Rare Musculoskeletal Condition | MT |
| 08-19 | US FDA approves Regeneron's rare bone disorder drug | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 80.91B | |||||
| 53.62B | |||||
| 50.13B | |||||
| 47.97B | |||||
| 31.41B | |||||
| 25.14B | - |
Select your edition
All financial news and data tailored to specific country editions
